Special Issue

Inherited Breast Cancer Risk: BRCA Mutations and Beyond

Message from the Guest Editors

The presence of pathogenic variants in cancerpredisposing genes has therapeutic implications for patients with breast cancer, and provides critical information for both cancer patients and healthy individuals in terms of prevention and early diagnosis. However, additional research to refine the treatment. surveillance and prevention strategies for individuals with pathogenic variants associated with an increased risk of breast cancer is warranted. We are pleased to invite you to submit an article to our Special Issue, "Inherited Breast Cancer Risk: BRCA Mutations and Beyond". This Special Issue aims to shed some light onto the treatment of patients with breast cancer carrying pathogenic variants in cancer-predisposing genes, evaluate the benefit of cancer prevention strategies in healthy individuals and assess current or proposed early diagnosis screening protocols. We look forward to receiving your contributions.

Guest Editors

Prof. Dr. George Fountzilas

1. Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece 2. Department of Medical Oncology, German Oncology Center, Limassol, Cyprus

Dr. Helena Linardou

4th Oncology Department, Metropolitan Hospital, Athens, Greece
 Comprehensive Clinical Trials Center, Metropolitan Hospital, Athens, Greece

Dr. Alexia Eliades

Medicover Genetics, Nicosia, Cyprus

Deadline for manuscript submissions

closed (20 August 2024)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/152757

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

